10/11/2020
Boards of Appeal has issued the written grounds with respect to priority invalidity in the so-called CRISPR case.
The reasoning of the Boards of Appeal does not change the general principles already applied by the European Patent Office. It is critical to keep track of applicants in a priority-founding application and applicants in a follow-up application claiming priority. It is clearly stated after the decision, T844/18. Here, the European patent, EP 2 771 468, was declared invalid for lack of novelty because priority was not valid.
One of the inventors originally listed as an applicant in the priority-founding US patent application was not to be found as an applicant in the subsequent PCT application. This PCT application was later filed as a European patent application. This proved to be invalidating, since priority under Article 87 (1) of the European Patent Office can only be claimed with the same applicant(s) or with formally correct assignment of rights prior to filing.
Typically, inventors are listed as applicants in U.S. patent applications. The decision is another reminder of the importance of keeping track of both inventors and applicants when filing national patent applications around the world. In this case, invalid priority was devastating, as there was novelty destroying material in the intervening period.
Share:
Share:
Kanved Patent Consulting is a full-service patent agency, specialized in technical, legal and strategic counseling in the field of patents and industrial designs. We have the capacity, experience and knowledge to advise in the field of intangible assets, from protection with patents and utility models to copyright, licensing and protection of trade secrets. Together, we convert your ideas into successful business propositions.
Kanved Patent Consulting ApS
Advice House
Lysholt Allé 10
7100 Vejle
Denmark (DK)
Tel: +45 70 70 70 28
Email: info@kanved.com
Vat. No. 38 98 17 65